Leerink Partners analyst Geoff Porges reiterated a Buy rating on FibroGen (NASDAQ:FGEN) on Tuesday, setting a price target of $56, which is approximately 165.03% above the present share price of $21.13.
Porges expects FibroGen to post earnings per share (EPS) of -$0.64 for the second quarter of 2021.
The current consensus among 11 TipRanks analysts is for a Moderate Buy rating of shares in FibroGen, with an average price target of $44.43.
The analysts price targets range from a high of $56 to a low of $28.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $65 million and a net profit of -$58 million. The company's market cap is $1.95 billion.
According to TipRanks.com, Leerink Partners analyst Geoff Porges is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 4.8% and a 47.62% success rate.
FibroGen, Inc. engages in the discovery, development, and commercialization of therapeutics. It focuses on hypoxia-inducible factor and connective tissue growth factor biology to develop innovative medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.